514LBA (PB-514) LBA Posters: Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

Authors:
  • BWB. Wolpin
    B. Wolpin
  • DHD. Hong
    D. Hong
  • ASA. Spira
    A. Spira
  • ASA. Starodub
    A. Starodub
  • WPW. Park
    W. Park
  • DSD. Sommerhalder
    D. Sommerhalder
  • JVJ. Valerin
    J. Valerin
  • MBM. Barve
    M. Barve
  • SPS. Punekar
    S. Punekar
  • MPM. Pelster
    M. Pelster
  • BHB. Herzberg
    B. Herzberg
  • NAN. Azad
    N. Azad

Abstract
No abstract available